Skip to main content
Premium Trial:

Request an Annual Quote

Choices, Choices

At Motley Fool, Brian Orelli sizes up both Pacific Biosciences and Complete Genomics to determine which one is the "better buy." Orelli notes that some analysts are skeptical about sequencing's prospects, though he isn't since there is a demand for sequencing and because "the bust [is] still many years away." As for choosing between the two companies, Orelli says, "It's too early to make a definitive call, but of the two, I like PacBio better because I'm not fond of the low-cost, high-volume business model." There is also a poll going on over there, so let your thoughts be known.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.